Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
South Plains Oncology Consortium
In this study, an initial Phase I component of six patients will be conducted to monitor for potential toxicities as this wil be the initial adult experience of fenretinide (4-HPR) given together with ketoconazole
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Recurrent epithelial ovarian cancer or primary peritoneal carcinoma that can be platinum sensitive or platinum resistant
SWOG Performance Status 0-2
Previously received a platinum and paclitaxel containing regimen
Projected Life Expectancy of at least 3 months
Adequate bone marrow function
Adequate organ function
Must have received at least 1 prior salvage regimen for recurrent ovarian cancer
Recovery from acute toxicities from surgery, radiation or chemotherapy
At least 3 weeks from last therapy
You may not be if
Prior fenretinide oral capsule use allowed. If prior IV fenretinide use, must contact study chair for eligibility
Second malignancy within last 5 years
Use of concomitant antioxidants, such as vitamin C or E
Untreated or symptomatic brain metastases
History of hypertriglyceride levels \> 200 mg/dl; triglyceride levels \< 200 and receiving treatment are okay.
Use of certain medications is prohibited - contact study coordinator for information
